Grifols SA (GRFS)
9.545
+0.48
(+5.24%)
USD |
NASDAQ |
Nov 14, 16:00
9.545
0.00 (0.00%)
After-Hours: 20:00
Grifols Research and Development Expense (Quarterly): 96.65M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 96.65M |
| June 30, 2024 | 97.66M |
| December 31, 2023 | 122.32M |
| September 30, 2023 | 95.46M |
| June 30, 2023 | 96.60M |
| December 31, 2022 | 108.64M |
| September 30, 2022 | 94.30M |
| June 30, 2022 | 90.67M |
| June 30, 2021 | 104.53M |
| March 31, 2021 | 86.53M |
| December 31, 2020 | 96.28M |
| September 30, 2020 | 83.44M |
| June 30, 2020 | 81.77M |
| March 31, 2020 | 74.89M |
| December 31, 2019 | 83.08M |
| September 30, 2019 | 76.07M |
| June 30, 2019 | 78.60M |
| March 31, 2019 | 71.12M |
| December 31, 2018 | 80.07M |
| September 30, 2018 | 67.71M |
| June 30, 2018 | 69.59M |
| March 31, 2018 | 66.30M |
| December 31, 2017 | 125.34M |
| September 30, 2017 | 70.90M |
| June 30, 2017 | 68.66M |
| Date | Value |
|---|---|
| March 31, 2017 | 63.03M |
| December 31, 2016 | 51.74M |
| September 30, 2016 | 58.39M |
| June 30, 2016 | 56.13M |
| March 31, 2016 | 52.58M |
| December 31, 2015 | 72.28M |
| September 30, 2015 | 60.23M |
| June 30, 2015 | 58.59M |
| March 31, 2015 | 57.45M |
| December 31, 2014 | 66.46M |
| September 30, 2014 | 56.12M |
| June 30, 2014 | 64.87M |
| March 31, 2014 | 51.92M |
| December 31, 2013 | 44.94M |
| September 30, 2013 | 42.13M |
| June 30, 2013 | 38.09M |
| March 31, 2013 | 38.69M |
| December 31, 2012 | 44.20M |
| September 30, 2012 | 39.59M |
| June 30, 2012 | 38.99M |
| March 31, 2012 | 37.15M |
| December 31, 2011 | 41.73M |
| September 30, 2011 | 39.89M |
| June 30, 2011 | 26.91M |
| March 31, 2011 | 15.71M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
74.89M
Minimum
Mar 2020
122.32M
Maximum
Dec 2023
94.19M
Average
95.46M
Median
Sep 2023
Research and Development Expense (Quarterly) Benchmarks
| Cellectis SA | 23.83M |
| Adaptimmune Therapeutics PLC | 40.45M |
| Akari Therapeutics PLC | 3.314M |
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | 10.55M |